Not Signed In - European Medicines Agency concludes action on COX-2 inhibitors
Fri, 01 Jul 2005 06:00 AM EST
... Concluding its review of the class of COX-2 inhibitors, the European Medicines Agency (EMEA) has recommended the suspension of the marketing authorisation for Bextra (valdecoxib) and recommended new contraindications and warnings for other COX-2 inhibitors that continue to be available in the European Union (EU)... click link for more info. ...
Related Topics
- COX-2 Inhibitors
- Black Alder
- Drowsiness and other side effects of medicines
- Celecoxib
- ACE Inhibitors
- MAO Inhibitors
- Proton-pump Inhibitors
- Rofecoxib
- Development of antibodies (inhibitors) to fibrinogen with treatment
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Adoption
- Over-the-Counter Medicines
- Olanzapine
- Aging
- Persons with Disabilities
- Foster Care
- Rosuvastatin
- European Goldenrod
- Atherosclerosis
- Home Care
email this page
print this page
bookmark this page
feedback on this page
